Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421459 · ClinicalTrials.gov registry record · Phase 3
A Study in Adults With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 759
- Enrollment target
NCT01421459 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 759 participants.
The verdict
NCT01421459, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 759 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
Interventions
- DRUG LY2963016
- DRUG Lantus
- DRUG OAMs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 759 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421459
The ClinicalTrials.gov registry entry for NCT01421459 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 759 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LY2963016 is the first listed.
NCT01421459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01421459 about?
NCT01421459 is a clinical study titled "A Study in Adults With Type 2 Diabetes". The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
What is the current status of trial NCT01421459?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 759 participants. The study started on 2011-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01421459?
The interventions under investigation include: LY2963016 (DRUG), Lantus (DRUG), OAMs (DRUG).
Who is sponsoring clinical trial NCT01421459?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.